Plasma mutation profile of precursor lesions and colorectal cancer using the Oncomine Colon cfDNA Assay.

ABSTRACT:

Background

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Early detection of precursor lesions or early-stage cancer could hamper cancer development or improve survival rates. Liquid biopsy, which detects tumor biomarkers, such as mutations, in blood, is a promising avenue for cancer screening.

Aim

To assess the presence of genetic variants in plasma cell-free tumor DNA from patients with precursor lesions and colorectal cancer using the commercial Oncomine Colon cfDNA Assay.

Material and methods

Cell-free DNA (cfDNA) samples from the plasma of 52 Brazilian patients were analyzed. Eight patients did not have any significant lesions (five normal colonoscopies and three hyperplastic polyps), 24 exhibited precursor lesions (13 nonadvanced

SUBMITTER: Dos Reis MB 

PROVIDER: S-EPMC11657448 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature